Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 488,100 | 403,800 | 434,215 | 470,783 | 662,205 |
| Marketable Securities | 1,176,400 | 1,208,900 | 1,362,017 | 404,695 | 334,473 |
| Receivables | 452,500 | 489,000 | 494,645 | 423,537 | 419,424 |
| Inventories | 760,000 | 780,500 | 719,316 | 572,239 | 622,253 |
| Other current assets | 30,700 | 26,100 | 23,604 | 10,089 | 10,859 |
| TOTAL | $3,030,300 | $3,048,300 | $3,157,976 | $1,990,479 | $2,139,835 |
| Non-Current Assets | |||||
| PPE Net | 528,100 | 529,000 | 498,612 | 511,639 | 491,371 |
| Investments And Advances | 4,839,200 | 7,698,100 | 8,830,892 | 14,387,010 | 9,561,140 |
| Intangibles | 704,100 | 734,100 | 738,635 | 601,282 | 491,413 |
| Other Non-Current Assets | 262,400 | 289,600 | 275,551 | 308,979 | 288,856 |
| TOTAL | $6,333,800 | $9,250,800 | $10,343,690 | $15,808,910 | $10,832,780 |
| Total Assets | $9,364,100 | $12,299,100 | $13,501,670 | $17,799,390 | $12,972,620 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,200 | 500 | 465 | 489 | 1,798 |
| Accounts payable and accrued liabilities | 122,300 | 144,600 | 135,041 | 141,941 | 139,451 |
| Accrued Expenses | 124,200 | 139,900 | 194,790 | 276,986 | 222,875 |
| Other current liabilities | 147,200 | 161,600 | 169,648 | 127,936 | 131,102 |
| TOTAL | $467,800 | $522,800 | $568,708 | $680,938 | $631,536 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,200,400 | 1,199,100 | 1,197,716 | 10,514 | 12,258 |
| Deferred Revenues | N/A | N/A | N/A | 50,852 | 42,468 |
| Other Non-Current Liabilities | 308,600 | 360,500 | 349,509 | 358,129 | 372,099 |
| TOTAL | $2,327,000 | $3,035,100 | $3,317,706 | $3,433,219 | $2,461,142 |
| Total Liabilities | $2,794,800 | $3,557,900 | $3,886,414 | $4,114,157 | $3,092,678 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 28,011 | 28,518 | 29,596 | 29,932 | 29,844 |
| Common Shares | N/A | N/A | 3 | 3 | 3 |
| Retained earnings | 7,416,400 | 9,260,600 | 9,898,203 | 13,525,340 | 9,268,012 |
| Other shareholders' equity | -538,300 | -335,500 | -466,408 | -175,836 | 282,549 |
| TOTAL | $6,569,300 | $8,741,200 | $9,615,252 | $13,685,240 | $9,879,940 |
| Total Liabilities And Equity | $9,364,100 | $12,299,100 | $13,501,666 | $17,799,397 | $12,972,618 |